Hypothesis

Blocking mitochondrial DNA (mtDNA) release from senescent T cells interrupts the immune‑driven aging loop and extends healthspan independent of thymic output.

Mechanistic Rationale

Aged T cells accumulate mitochondrial dysfunction [5] and become senescent, secreting SASP that induces bystander senescence [3][4]. Beyond cytokines, damaged mitochondria release mtDNA into the cytosol and extracellular space via mitochondrial permeability transition pore (mPTP) opening or extracellular vesicle shedding. Circulating mtDNA acts as a damage‑associated molecular pattern (DAMP) that activates the cGAS‑STING pathway in stromal and innate immune cells, triggering NF‑κB‑dependent interferon signaling and reinforcing SASP production in a paracrine loop. This mtDNA‑cGAS‑STING axis therefore links T‑cell mitochondrial failure to tissue‑wide inflammaging and senescence amplification, offering a point of intervention upstream of thymic involution.

Experimental Design

1. Model: Transfer splenocytes from 24‑month‑old mice into 2‑month‑old recipients (established senescence‑inducing paradigm) [1].
2. Intervention: Treat recipients with a selective mPTP inhibitor (e.g., sanglifehrin A analog) or overexpress DNase2 in tissue macrophages via AAV‑mediated delivery to degrade extracellular mtDNA.
3. Controls: Vehicle‑treated recipients; recipients receiving young splenocytes; recipients receiving aged splenocytes plus a non‑active analog.
4. Readouts (4‑week endpoint):
   • Serum mtDNA levels (qPCR for mitochondrial‑encoded genes).
   • cGAS‑STING activation in liver/kidney lysates (phospho‑TBK1, IRF3 Western blot).
   • Senescence biomarkers (p16^Ink4a^, SA‑β‑gal) in non‑lymphoid tissues.
   • SASP cytokine panel (IL‑6, TNF‑α, CCL2) by multiplex assay.
   • Functional frailty (grip strength, treadmill endurance) and histological tissue damage.
5. Reversal arm: In aged mice, administer the same mtDNA‑targeting therapy and assess whether existing senescence markers decline.

Predicted Outcomes

If mtDNA efflux is a critical mediator, inhibitor/DNase2 groups will show:

• Significant reduction in circulating mtDNA vs. aged‑splenocyte controls.
• Lower cGAS‑STING signaling and downstream NF‑κB activity.
• Decreased p16^Ink4a^+ cells and SA‑β‑gal activity in liver/kidney.
• Attenuated SASP cytokine surge.
• Improved frailty scores comparable to young‑splenocyte recipients. Conversely, blocking mtDNA should not affect thymic naïve T‑cell output, proving the effect is independent of thymic rejuvenation.

Potential Caveats

• mtDNA may also act as a vaccine‑like stimulus; chronic suppression could impair host defense against intracellular pathogens. Include infection challenge (e.g., Listeria monocytogenes) to assess immunity.
• mPTP inhibitors can affect mitochondrial metabolism broadly; use tissue‑specific delivery or inducible DNase2 to limit off‑target effects.
• Human relevance: validate findings with peripheral blood mtDNA and cGAS‑STING activation in elderly donors before/after senolytic or mPTP‑modulating drugs.